A follow - up of the 48 patients who were
evaluable at a median time of 24 months indicated no statistical differences between the two groups in terms of overall or progression - free survival.
Not exact matches
Eight of nine patients who are
evaluable for response had no evidence of disease in their bone marrow
at three months, and all remain in remission after a median follow - up period of six months, with a range from 0.5 to 9 months.
Among 30 patients who were
evaluable for response, 4 of 13 responded
at the lower dose (one complete remission and three partial responses, ORR = 31 percent) and nine of 17 responded
at the higher dose (six complete remissions and three partial responses, ORR = 53 percent).
The early numbers
at AACR: 15 of 69
evaluable patients (22 percent) who had failed a median of two treatments, including checkpoint therapy, responded to the CMP -001-pembrolizumab combination.